C O Bingham 3rd
Overview
Explore the profile of C O Bingham 3rd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bartlett S, Gutierrez A, Butanis A, Bykerk V, Curtis J, Ginsberg S, et al.
Qual Life Res
. 2018 May;
27(9):2443-2451.
PMID: 29797175
Purpose: Fatigue is frequent and often severe and disabling in RA, and there is no consensus on how to measure it. We used online surveys and in-person interviews to evaluate...
2.
Puzanov I, Diab A, Abdallah K, Bingham 3rd C, Brogdon C, Dadu R, et al.
J Immunother Cancer
. 2017 Nov;
5(1):95.
PMID: 29162153
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete...
3.
Emery P, Bingham 3rd C, Burmester G, Bykerk V, Furst D, Mariette X, et al.
Ann Rheum Dis
. 2016 Aug;
75(10):e69.
PMID: 27519773
No abstract available.
4.
Emery P, Bingham 3rd C, Burmester G, Bykerk V, Furst D, Mariette X, et al.
Ann Rheum Dis
. 2016 May;
76(1):96-104.
PMID: 27165179
Objectives: To assess the efficacy and safety of certolizumab pegol (CZP)+dose-optimised methotrexate (MTX) versus placebo (PBO)+dose-optimised MTX in inducing and sustaining clinical remission in DMARD-naïve patients with moderate-to-severe, active, progressive...
5.
Curtis J, Yang S, Chen L, Pope J, Keystone E, Haraoui B, et al.
Arthritis Care Res (Hoboken)
. 2015 May;
67(10):1345-53.
PMID: 25988705
Objective: Simplified measures to quantify rheumatoid arthritis (RA) disease activity are increasingly used. The minimum clinically important differences (MCID) for some measures, such as the Clinical Disease Activity Index (CDAI),...
6.
Muhit A, Arora S, Ogawa M, Ding Y, Zbijewski W, Stayman J, et al.
Proc SPIE Int Soc Opt Eng
. 2014 Aug;
8672:867203.
PMID: 25076823
Purpose: We describe the initial assessment of the peripheral quantitative CT (pQCT) imaging capabilities of a cone-beam CT (CBCT) scanner dedicated to musculoskeletal extremity imaging. The aim is to accurately...
7.
Tak P, Mease P, Genovese M, Kremer J, Haraoui B, Tanaka Y, et al.
Arthritis Rheum
. 2012 Mar;
64(2):360-70.
PMID: 22389919
Objective: To evaluate the safety and efficacy of ocrelizumab plus methotrexate (MTX) or leflunomide (LEF) in patients with active rheumatoid arthritis (RA) and an inadequate response to tumor necrosis factor...
8.
Manno R, Bingham 3rd C, Paternotte S, Gossec L, Halhol H, Giacovelli G, et al.
Osteoarthritis Cartilage
. 2011 Dec;
20(2):93-101.
PMID: 22178465
Objective: Total joint replacement has been proposed as an endpoint in disease modifying osteoarthritis drug (DMOAD) randomized clinical trials (RCTs); however, disparities have generated concerns regarding this outcome. A combined...
9.
Bingham 3rd C, Bird S, Smugar S, Xu X, Tershakovec A
Osteoarthritis Cartilage
. 2008 Jun;
16(11):1289-93.
PMID: 18514551
Objectives: To determine the proportion of responders in two identical osteoarthritis (OA) trials using Outcome Measures in Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) criteria and to assess the comparability...
10.
Furst D, Halbert R, Bingham 3rd C, Fukudome S, Anderson L, Bonafede P, et al.
Rheumatology (Oxford)
. 2008 Jan;
47(2):194-9.
PMID: 18178593
Objectives: There is a lack of agreement on assessing disease activity in patients with RA and determining when the RA treatment should be changed or continued. A panel of rheumatologists...